{"organizations": [], "uuid": "ecbe59cca411dd298c95f036ffca82d7eac42d90", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-apricus-biosciences-receives-compl/brief-apricus-biosciences-receives-complete-response-letter-from-fda-for-vitaros-idUSASB0C65Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-16T14:39:00.000+02:00", "replies_count": 0, "uuid": "ecbe59cca411dd298c95f036ffca82d7eac42d90"}, "author": "", "url": "https://www.reuters.com/article/brief-apricus-biosciences-receives-compl/brief-apricus-biosciences-receives-complete-response-letter-from-fda-for-vitaros-idUSASB0C65Q", "ord_in_thread": 0, "title": "BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "apricus biosciences inc", "sentiment": "none"}, {"name": "vitaros reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "crl", "sentiment": "none"}, {"name": "apricus biosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 16, 2018 / 12:40 PM / in 11 minutes BRIEF-Apricus Biosciences Receives Complete Response Letter From FDA For Vitaros Reuters Staff Feb 16 (Reuters) - Apricus Biosciences Inc: * APRICUS BIOSCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR VITAROS * APRICUS BIOSCIENCES INC - CRL INDICATES THAT FDA CANNOT APPROVE NDA FOR VITAROS IN ITS PRESENT FORM * APRICUS BIOSCIENCES INC - CRL IDENTIFIES DEFICIENCIES RELATED TO CHEMISTRY, MANUFACTURING AND CONTROL FOR VITAROS * APRICUS BIOSCIENCES - CRL ALSO IDENTIFIES CERTAIN SAFETY CONCERNS SPECIFIC TO 2.5% CONCENTRATION OF DDAIP.HCL IN CURRENT FORMULATION FOR VITAROS * APRICUS BIOSCIENCES INC - GOAL OF PROVIDING MARKET AN UPDATE ON CRL ASSESSMENT IN EARLY MARCH OF THIS YEAR Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-16T14:39:00.000+02:00", "crawled": "2018-02-16T14:58:30.010+02:00", "highlightTitle": ""}